Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 32.52M P/E - EPS this Y -4.50% Ern Qtrly Grth -
Income -15.43M Forward P/E -2.74 EPS next Y -8.60% 50D Avg Chg -8.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 2.37 EPS next 5Y - 52W High Chg -39.00%
Recommedations 2.00 Quick Ratio 5.02 Shares Outstanding 26.40M 52W Low Chg 194.00%
Insider Own 45.91% ROA -57.92% Shares Float 14.09M Beta 0.05
Inst Own 8.57% ROE -106.23% Shares Shorted/Prior 349.89K/316.56K Price 2.00
Gross Margin - Profit Margin - Avg. Volume 257,740 Target Price 14.00
Oper. Margin - Earnings Date - Volume 49,984 Change -2.44%
About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc. News
04/18/24 Immix Biopharma on Track to Dose NXC-201 Patients in United States
04/15/24 Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
03/20/24 Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
03/05/24 Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
02/21/24 Immix Biopharma 12 Month Review Progress Update
02/08/24 Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
02/07/24 Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
02/05/24 Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
02/05/24 Immix Biopharma Announces Proposed Public Offering of Common Stock
01/24/24 Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
01/11/24 Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
01/04/24 Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
12/18/23 Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
12/15/23 Insider Spends US$267k Buying More Shares In Immix Biopharma
12/11/23 Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
11/30/23 Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
11/28/23 What Makes Immix Biopharma, Inc. (IMMX) a Good Fit for 'Trend Investing'
11/24/23 Pleasing Signs As A Number Of Insiders Buy Immix Biopharma Stock
11/22/23 Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down
11/22/23 Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
IMMX Chatroom

User Image keebs107 Posted - 3 hours ago

$IMMX

User Image SDBiotechInvestor Posted - 23 hours ago

$IMMX - late breaking abstract will be out next Friday at 4:30 PM EST

User Image keebs107 Posted - 23 hours ago

$IMMX

User Image RiccoTheGreat2 Posted - 1 day ago

@JhonHack I apologize for the misunderstanding, I thought I was making the post on the $IMMX board. Believe me it’s a bigger shit show over there.

User Image 777forme Posted - 1 day ago

$IMMX LGVN went from $3 to $43 in a week. Trying to be patient with this one

User Image Daddy044 Posted - 2 days ago

$IMMX my guess is deal guys dumped. news has been good. i think it bottomed

User Image MKGroupChicago Posted - 2 days ago

$IMMX

User Image keebs107 Posted - 2 days ago

$IMMX

User Image moneygrabber55 Posted - 3 days ago

$IMMX anyone here?

User Image moneygrabber55 Posted - 3 days ago

$IMMX anybody here

User Image MKGroupChicago Posted - 3 days ago

$IMMX may 7th

User Image WinPlaceShow Posted - 3 days ago

$IMMX I'd sell my shares and just be done with this crap but I wouldn't want to it drop any more for those of you that are left 🤣🤣 (shedding real tears here)

User Image Lastcall Posted - 3 days ago

$IMMX Loaded 1.98

User Image SDBiotechInvestor Posted - 4 days ago

$IMMX bought some. Seems like good buy ahead of May's oral presentation.

User Image DD_investments Posted - 4 days ago

$IMMX this has been on a downtrend for a few months but the drop the past week is brutal. Any news about delays?

User Image barryj18 Posted - 4 days ago

$IMMX we need more pumpers in here............where ya'll at?!?!? start buying ASAP, this is going to the moon!!! let's goooooo

User Image Lastcall Posted - 4 days ago

$IMMX 70 cents lower then offering price ..Think I will pick up a few

User Image Bionco Posted - 4 days ago

$IMMX buying zone

User Image _zenvest Posted - 5 days ago

$IMMX this company either getting acquired or they just basically lied to everyone about their MM data being so positive. There’s no way they just stopped treating patients 3/4 of the way through with positive data such as that.

User Image keebs107 Posted - 6 days ago

$IMMX

User Image MKGroupChicago Posted - 1 week ago

$IMMX

User Image Lastcall Posted - 1 week ago

$IMMX This might be why the drop black box label for Car -T drugs https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-mandates-label-updates-car-t-cancer-therapies-2024-04-18/

User Image moneygrabber55 Posted - 1 week ago

$IMMX any reason for this drop?

User Image moneygrabber55 Posted - 1 week ago

$IMMX wow, this is brutal

User Image MKGroupChicago Posted - 1 week ago

$IMMX today is my 2nd year with this stock. At this point I think I am a majority holder 😂

User Image mdrins00 Posted - 1 week ago

$IMMX it's official. apparently no good news will make this stock move! late breaker oral at ASGCT? meh announcement of timeline to start NXC-201 dosing? meh 'course, with these guys you never know what "mid-2024" means. you and i might think "June", right? well, i guess we'll see. and even if it is June, that still a delay of 7-8 mos since their IND clearance. this crew moves very, very slowly. and, because there have been no updates on the IMX or MM programs, they are basically a one-trick pony at this point...NXC-201 in AL Amyloidosis. maybe that's the "market discount" that is being applied here?

User Image Expert33 Posted - 1 week ago

$IMMX One of these days...

User Image _zenvest Posted - 1 week ago

$IMMX AND…..where is the data, on any trial, Its been 7 MONTHS!!

User Image Daddy044 Posted - 1 week ago

$IMMX Good news so much for that "Significant Delay" from an unnamed source

User Image _zenvest Posted - 1 week ago

$IMMX what about Multiple myeloma and IMMX PIPELINE!!!!

Analyst Ratings
Roth MKM Buy Aug 14, 23
Roth MKM Buy Feb 22, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hsu Jason Director Director Dec 08 Buy 4.78 56,000 267,680 813,000 12/12/23
Hsu Jason Director Director Sep 11 Buy 2.7 72,000 194,400 757,000 09/18/23
Ng Carey Director Director Sep 14 Buy 2.576 10,000 25,760 10,000 09/15/23
Adams Helen C. Director Director Sep 12 Buy 2.9609 13,000 38,492 13,000 09/14/23
Hsu Jason Director Director Sep 08 Buy 2.5317 10,000 25,317 685,000 09/12/23
BUCHAN MELISSA JANE Director Director Sep 07 Buy 2.4613 20,000 49,226 20,000 09/11/23
Marquet Magda Director Director Sep 06 Buy 2.4681 9,000 22,213 20,000 09/08/23
Marquet Magda Director Director Aug 31 Buy 2.01 1,000 2,010 1,000 09/05/23
Senn Sean 10% Owner 10% Owner Jul 14 Sell 2.75 200 550 899,800 07/18/22